Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugs - 02/09/11
Doi : 10.1016/S0002-9343(02)01363-3
Janyce F Rogers, PharmD a, Anne N Nafziger, MD, MHS a, b, Joseph S Bertino, PharmD a, b, ⁎ 
a Clinical Pharmacology Research Center (JFR, ANN, JSB), Bassett Healthcare, Cooperstown, New York, USA
b Department of Medicine (ANN, JSB), Bassett Healthcare, Cooperstown, New York, USA
*Requests for reprints should be addressed to Joseph S. Bertino, Jr, PharmD, Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, New York 13326-1394, USA
Abstract |
Drug-metabolizing enzyme activity is one of many factors affecting patient response to medications. The objective of this review is to highlight the potential for genetic variability in cytochrome P450 enzyme activity that can lead to interperson differences in response to drugs. Awareness and application of this knowledge will improve drug use in clinical practice and provide the physician with further appreciation that standard drug dosing may not be appropriate in all patients.
Le texte complet de cet article est disponible en PDF.Plan
© 2002
Excerpta Medica Inc. Tous droits réservés.
Vol 113 - N° 9
P. 746-750 - décembre 2002 Retour au numéro
Article précédent
- Quality markers of drug information on the internet: an evaluation of sites about St. John’s Wort
- Meret Martin-Facklam, Michael Kostrzewa, Falk Schubert, Christiane Gasse, Walter E Haefeli
- Benign migratory glossitis or geographic tongue: an enigmatic oral lesion
- Dimitrios Assimakopoulos, George Patrikakos, Christina Fotika, Moses Elisaf
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?